Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Stronger Racial and Ethnic Minority Presence Is Needed in Clinical Cancer Trials

August 12th 2020

Numerous analyses conducted over the past few years have underscored a serious issue in clinical cancer trials that needs to be addressed: a lack of racial and ethnic diversity among participants.

Radiation/ADT Use in High-Risk Prostate Cancer Can Be Personalized

August 12th 2020

Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.

Intense Neoadjuvant ADT Prior to Radical Prostatectomy Leads to Promising pCRs in High-Risk Prostate Cancer

August 11th 2020

Rana R. McKay, MD, discusses the benefit of intense neoadjuvant hormone therapy prior to radical prostatectomy in men with high-risk prostate cancer and next steps for research.

Study Explores Genomics of Race in Prostate Cancer

August 6th 2020

Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.

Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

August 5th 2020

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Dr. Shore on Challenges with ADT in Recurrent Prostate Cancer

August 4th 2020

Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.

Dr. Agarwal on the Safety Profile of Olaparib in HRR Gene-Mutant mCRPC

August 4th 2020

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Dr. Shore on Unique Challenges in Nonmetastatic CRPC

August 3rd 2020

Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.

Dr. Morris on Next Steps for PSMA–Targeted PET Imaging in Prostate Cancer

July 30th 2020

Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Dr. Saad on the Clinical Impact of Apalutamide in nmCRPC

July 30th 2020

Fred Saad, MD, FRCS, discusses the impact of apalutamide on nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN trial.

Dr. Shore on Cardio-Oncology Strategies in Prostate Cancer

July 30th 2020

Neal D. Shore, MD, FACS, discusses the cardio-oncology strategies that can be implemented in patients with prostate cancer to reduce the chances of a cardio-related adverse-event.

FDA Provides Regulatory Clarity on Phase 3 Trial Design for VERU-111 in mCRPC

July 29th 2020

The FDA has provided regulatory clarity on the design of the pivotal phase 3 trial examining the first-in-class oral, oral, selective antitubulin agent VERU-111 in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Agarwal on the Progression of the COSMIC-021 Trial in mCRPC

July 29th 2020

Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer

July 29th 2020

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Dr. Gafita on the Opportunity for 177Lu-PSMA-617 in mCRPC

July 28th 2020

Andrei Gafita, MD, discusses available therapies for men with advanced castration-resistant prostate cancer.

Delayed LHRH Agonist Dosing Doubles Castration Levels in Prostate Cancer

July 28th 2020

The administration of luteinizing hormone-releasing hormone agonists in patients with prostate cancer was significantly more delayed in clinical practice than in pivotal clinical trials.

Salvage Lymph Node Dissection Shows Suboptimal Benefit in Node-Positive Prostate Cancer

July 24th 2020

Findings from a recent study published in European Urology show that salvage lymph node dissection alone is inadequate intervention for patients with prostate cancer and nodal recurrence.

Dr. Hope on Challenges With 68Ga-PSMA-11 PET in Prostate Cancer

July 23rd 2020

Thomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.

Shore Speaks to Updates Showcasing Benefits, Safety of Darolutamide in Nonmetastatic CRPC

July 23rd 2020

Neal Shore, MD, discusses the significantly improved overall survival in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.

Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer

July 22nd 2020

Arnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.